about
[Scleroderma-like lesions in the course of autoimmune hepatitis. Case report].Quality of life and satisfaction with life in SLE patients-the importance of clinical manifestations.Effective treatment of nodular amyloidosis with carbon dioxide laser.Correlation of endostatin and tissue inhibitor of metalloproteinases 2 (TIMP2) serum levels with cardiovascular involvement in systemic sclerosis patientsRepeated doses of UVR cause minor alteration in cytokine serum levels in humansThe imbalance between metalloproteinases and their tissue inhibitors is involved in the pathogenesis of dermatitis herpetiformisCan biologic treatment induce cutaneous focal mucinosis?Interleukin 6 and 8 levels in plasma and fibroblast cultures in psoriasis.Allergic diseases, drug adverse reactions and total immunoglobulin E levels in lupus erythematosus patients.Tumour necrosis factor-alpha polymorphism as one of the complex inherited factors in pemphigusEvaluation of caspase 1 and sFas serum levels in patients with systemic sclerosis: correlation with lung dysfunction, joint and bone involvement.Risk factors in Central Poland for the development of superficial and nodular basal cell carcinomas.Expression of selected integrins and selectins in bullous pemphigoid.Narrow band ultraviolet B irradiations cause alteration in interleukin-31 serum level in psoriatic patients.Serum concentration of interleukin-6 is increased both in active and remission stages of pemphigus vulgaris.Psoriasis rupioides: a rare variant of a common disease.Photoprovocation in cutaneous lupus erythematosus: a multicenter study evaluating a standardized protocol.The dynamism of cutaneous lupus erythematosus: mild discoid lupus erythematosus evolving into SLE with SCLE and treatment-resistant lupus panniculitis.[Chloroquine influence on lipid metabolism and selected laboratory parameters].Pathogenic activity of circulating anti-desmoglein-3 autoantibodies isolated from pemphigus vulgaris patients.Medium dose ultraviolet A1 phototherapy and mRNA expression of interleukin 8, interferon γ, and chemokine receptor 4 in acute skin lesions in atopic dermatitis.Sonic hedgehog pathway dysregulation in skin basal-cell carcinoma of a Polish population.Environmental risk factors predisposing to the development of basal cell carcinoma.Expression of selected adhesion molecules in dermatitis herpetiformis and bullous pemphigoid.An enhanced risk of basal cell carcinoma is associated with particular polymorphisms in the VDR and MTHFR genes.Disturbances of the expression of metalloproteinases and their tissue inhibitors cause destruction of the basement membrane in pemphigoid.IL-17 expression in dermatitis herpetiformis and bullous pemphigoid.1-Methylnicotinamide: a potent anti-inflammatory agent of vitamin origin.Correlations between concentrations of interleukin (IL)-17A, IL-17B and IL-17F, and endothelial cells and proangiogenic cytokines in systemic lupus erythematosus patients.Interleukin 4 plasma levels in psoriasis vulgaris patients.Pneumocystis carinii mimicking neonatal lupus erythematosus-related pneumonitis.Vitamin D serum level changes in psoriatic patients treated with narrowband ultraviolet B phototherapy are related to the season of the irradiation.Suppression of contact hypersensitivity after repeated exposures of humans to low doses of solar simulated radiation.Detection of pemphigus autoantibodies by IIF and ELISA tests in patients with pemphigus vulgaris and foliaceus and in healthy relatives.Peripheral blood lymphocyte apoptosis and circulating dendritic cells in patients with systemic lupus erythematosus: correlation with immunological status and disease-related symptoms.Histological examination in assessment of ultraviolet-induced suppression of contact hypersensitivity response.Acetylation genotype and phenotype in patients with systemic lupus erythematosus.Dermatitis artefacta in a patient with paranoid syndrome.Duration of Raynaud's phenomenon is negatively correlated with serum levels of interleukin 10 (IL-10), soluble receptor of interleukin 2 (sIL2R), and sFas in systemic sclerosis patients.Medium-dose ultraviolet A1 phototherapy improves SCORAD index and increases mRNA expression of interleukin-4 without direct effect on human β defensin-1, interleukin-10, and interleukin-31.
P50
Q33369491-FB5CBAF4-1D7D-42D1-9A10-5A17A38EBB20Q34014604-0FEFD078-6D46-4C3B-B926-7C0200190C80Q34413264-7747A082-DC46-40AF-8667-7F3ABDA1DFE6Q34894487-41B0EA2B-A3A9-4791-B173-1A192AAD8AA5Q34945391-CEC08E7C-8AA7-4924-9560-7CDD78067A52Q34945529-7361E598-7E82-41BB-BD38-B4DBA6F7548EQ34945870-AE68E91B-81B2-405F-8609-5C5C8C14DD39Q35039946-457B0049-7365-40A2-88D8-35688D269381Q35609293-A1D9FE92-56F5-494D-B382-228F8DE575C7Q35609374-A62D948C-D429-4C9C-8CD6-F0A821F614C8Q35609399-01BDF122-3657-41C4-869B-6DD4B4092016Q35762050-4B6AEE6D-44A4-47A3-A729-DFD3C22FE30EQ35791244-8F43ECB9-43E4-4C59-8E4C-79FD0BBBFE3BQ36710830-5B439BF6-9327-4186-95B1-BBDFA0F510D7Q36731758-2EC923D9-C995-404E-A3F4-FDE8A87CD062Q37948070-3BC18CED-DFDE-4145-B523-BC59729E3D69Q39748743-266BD839-5C8B-43F7-8674-6C2F52E2BA36Q41945460-632187BF-5E66-4824-9C28-32485F421F3CQ41945696-5A694E69-2F2B-4140-AC40-5C3D693AFFD7Q42001822-BEA4379D-8067-4CDB-B290-5D50505A0FEEQ42388410-0047A305-1685-4DB0-90F6-B1E40C61088AQ42448254-BB12A659-0279-48A4-8C8F-FEC07EE860BAQ42456953-003FB765-4ED0-4BA2-99B5-DC28D7503917Q42458287-242738BD-2B85-4C22-B8F3-255BAA6CDB43Q42491089-AB32FCC0-0756-486C-9A1C-DC8088EDFED2Q42502286-0A4910F9-D56F-4B69-A262-7C23887ED552Q42536070-A44B8781-DACC-444A-961A-2BF14FFDC728Q44510574-43E3A512-BF45-46FF-843F-9FD1EDF29EB6Q44651475-D539F9A9-8C3D-48A3-87F4-4E4D1485F359Q44811376-897FCEB7-96C3-45B5-9D47-8AA2ACDC4926Q44962953-C9E1F7BF-65CE-424B-AC1C-F95EC2F14A7DQ45900570-A4D49871-BE97-4397-89D8-3F6587653289Q46573273-58E5F38A-60F4-4B6E-9919-9EEDAFCCBF40Q46860186-B093DA0C-15C5-407B-94CC-B33B5DFE803FQ46908262-DA41A2D6-5431-46C4-A2BC-DECC06A97C9FQ46944039-EB20AE73-F963-4594-BE36-632951352291Q46986815-6C59D90F-4CB2-48DE-9258-FD06E4D13546Q47297508-19BA744E-9821-419B-A0E2-281F5EA2EC88Q47683237-5B4C7FC1-C65D-4D3E-BCF6-4C6C8CC1330CQ50243026-0F2E7BB3-7187-427D-950E-3EC7A1CB82E5
P50
name
Anna Sysa-Jedrzejowska
@ast
Anna Sysa-Jedrzejowska
@en
Anna Sysa-Jedrzejowska
@es
Anna Sysa-Jedrzejowska
@fr
Anna Sysa-Jedrzejowska
@nl
type
label
Anna Sysa-Jedrzejowska
@ast
Anna Sysa-Jedrzejowska
@en
Anna Sysa-Jedrzejowska
@es
Anna Sysa-Jedrzejowska
@fr
Anna Sysa-Jedrzejowska
@nl
altLabel
A Sysa-Jedrzejowska
@en
A. Sysa-Jedrzejowska
@en
Sysa-Jedrzejowska A
@en
Sysa-Jedrzejowska A.
@en
Sysa-Jedrzejowska
@en
prefLabel
Anna Sysa-Jedrzejowska
@ast
Anna Sysa-Jedrzejowska
@en
Anna Sysa-Jedrzejowska
@es
Anna Sysa-Jedrzejowska
@fr
Anna Sysa-Jedrzejowska
@nl
P214
P21
P213
0000 0004 0891 1706
P214
P31
P735
P7859
viaf-301829902